Trial Profile
A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Mitoxantrone
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 02 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 05 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Oct 2014.